Abstract
In January 2009, ustekinumab (Stelara; Janssen Cilag) was granted marketing authorization by the European Commission for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other therapies including cyclosporine, methotrexate and phototherapy.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Schon, M. P. & Boehncke, W. H. Psoriasis. N. Engl. J. Med. 352, 1899–1912 (2005).
Gottlieb, A. B. Psoriasis: emerging therapeutic strategies. Nature Rev. Drug Discov. 4, 19–34 (2005).
Torti, D. C. & Feldman, S. R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57, 1059–1068 (2007).
Yawalkar, N. et al. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111, 1053–1057 (1998).
Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125–130 (2004).
Hong, K. et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162, 7480–7491 (1999).
European Medicines Agency (EMEA). European Public Assessment Report – Stelara. EMEA website [online], (2008).
Kauffman, C. L. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest. Dermatol. 123, 1037–1044 (2004).
Toichi, E. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917–4926 (2006).
Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008).
Papp, K. A. et al.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).
Dubertret, L. et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol. 155, 729–736 (2006).
Rapp, S. R. et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401–407 (1999).
Reich, K. et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br. J. Dermatol. 28 Jan 2009 (epub ahead of print).
Augustin, M. et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216, 366–372 (2008).
Reich, K. et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr. Med. Res. Opin. 24, 1237–1254 (2008).
Schmitt J. et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br. J. Dermatol. 159, 513–526 (2008).
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
IMS MIDAS (2008).
IMS PADDS (2008).
Novarro, G. RBC Capital Markets Equity Research Report (RBC CM Research Publishing, Toronto, 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K.R. has received honoraria as consultant, advisory board member and acted as a paid speaker for Abbott, Biogen Idec, Centocor, UCB, Schering Plough, Wyeth and Merck Serono.
Rights and permissions
About this article
Cite this article
Reich, K., Yasothan, U. & Kirkpatrick, P. Ustekinumab. Nat Rev Drug Discov 8, 355–356 (2009). https://doi.org/10.1038/nrd2878
Issue date:
DOI: https://doi.org/10.1038/nrd2878
This article is cited by
-
Managing Macrophages in Rheumatoid Arthritis by Reform or Removal
Current Rheumatology Reports (2012)
-
Psoriasis market
Nature Reviews Drug Discovery (2009)
-
The role of interleukin-17 in the pathogenesis of rheumatoid arthritis
Current Rheumatology Reports (2009)
